Archive for July 29th, 2026

Targeting TDP-43 in ALS: Regulatory Hurdles, Trial Design Deficiencies, and the Causal Evidence Gap for CTx1000

Posted by Michael A. S. Guth on July 29th, 2026

๐€๐ฆ๐ฒ๐จ๐ญ๐ซ๐จ๐ฉ๐ก๐ข๐œ ๐ฅ๐š๐ญ๐ž๐ซ๐š๐ฅ ๐ฌ๐œ๐ฅ๐ž๐ซ๐จ๐ฌ๐ข๐ฌ (๐€๐‹๐’) ๐ข๐ฌ ๐š ๐Ÿ๐š๐ญ๐š๐ฅ ๐ง๐ž๐ฎ๐ซ๐จ๐๐ž๐ ๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐ฏ๐ž ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž. ๐Œ๐ž๐๐ข๐š๐ง ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐š๐ฅ ๐Ÿ๐ซ๐จ๐ฆ ๐ฌ๐ฒ๐ฆ๐ฉ๐ญ๐จ๐ฆ ๐จ๐ง๐ฌ๐ž๐ญ ๐ข๐ฌ ๐Ÿ๐Ÿ’ ๐ญ๐จ ๐Ÿ’๐Ÿ– ๐ฆ๐จ๐ง๐ญ๐ก๐ฌ, ๐š๐ง๐ ๐Ÿ๐จ๐ซ ๐ฆ๐จ๐ฌ๐ญ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ, ๐ง๐จ ๐š๐ฏ๐š๐ข๐ฅ๐š๐›๐ฅ๐ž ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ ๐ฆ๐ž๐š๐ง๐ข๐ง๐ ๐Ÿ๐ฎ๐ฅ๐ฅ๐ฒ ๐ฌ๐ฅ๐จ๐ฐ๐ฌ ๐ญ๐ก๐š๐ญ ๐๐ž๐œ๐ฅ๐ข๐ง๐ž. Since riluzole’s 1995 approval โ€” which extended median survival by only weeks โ€” more than 60 compounds have entered clinical trials for ALS, and nearly […]

Posted in Aging Adults, Neuroplasticity, Regulatory Medical Writing No Comments »
Read More »